Oncosil Medical Ltd

Research Oncosil Medical Ltd (OSL) on Bullrun: market cap AUD 35.52M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is AUD 35.52M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025AUD 1.17M-AUD 15.10M-AUD 12.08M-92.5%-1.37AUD 5.11MAUD 69.92KAUD 3.10M
FY2024AUD 516.63K-AUD 12.38M-AUD 11.32M-192.2%-2.23AUD 4.50MAUD 70.67KAUD 4.59M
FY2023AUD 367.68K-AUD 11.34M-AUD 11.37M-332.1%-3.76AUD 9.39MAUD 170.81KAUD 9.88M
FY2022AUD 231.79K-AUD 10.73M-AUD 10.12M-319.6%-4.03AUD 11.28MAUD 304.21KAUD 11.16M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-23AUD 35.52Mn/an/a0

Dividend history

Latest trailing dividend snapshot: annual dividend/share 0 AUD.

About Oncosil Medical Ltd

OncoSil Medical Limited, a medical device company, develops and commercializes localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. The company's lead product is OncoSil, a single-use brachytherapy device for the treatment of patients with locally advanced pancreatic cancer in combination with gemcitabine-based chemotherapy. OncoSil Medical Limited was incorporated in 2005 and is headquartered in Macquarie Park, Australia.

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Oncosil Medical Ltd's market cap?

Oncosil Medical Ltd's market capitalization is AUD 35.52M.

What does Oncosil Medical Ltd do?

OncoSil Medical Limited, a medical device company, develops and commercializes localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. The company's lead product is OncoSil, a single-use brachytherapy device for the treatment of patients with locally advanced pancreatic cancer in combination with gemcitabine-based chemotherapy. OncoSil Medical Limited was incorporated in 2005 and is headquartered in Macquarie Park, Australia.